2026-01-04 - Analysis Report
Here's a comprehensive analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data:

**0) Overview:**

This report provides a financial analysis of Recursion Pharmaceuticals Inc. (RXRX), comparing its performance against the S&P 500 (VOO), examining recent stock fluctuations, key indicators, news events, analyst opinions, and financial data to assess its current investment potential.

**1) Performance vs. S&P 500 (VOO):**

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover, develop, and commercialize novel therapeutics.
*   **RXRX Cumulative Return:** -31.43%
*   **VOO (S&P 500) Cumulative Return:** 39.85%
*   **Divergence:** The cumulative return of RXRX underperforms the S&P 500 significantly.
    *   *Current Divergence:* -71.3
    *   *Relative Divergence:* 2.4 (Near the bottom of its historical range)
*   **Analysis of Alpha, Beta, CAGR, MDD:**

| Year       | CAGR   | MDD   | Alpha   | Beta | Cap(B) |
|------------|--------|-------|---------|------|--------|
| 2022-2024  | 11.0%  | 55.8% | -9.0%   | 2.3  | 3.5    |
| 2023-2025  | 9.0%   | 59.2% | -53.0%  | 2.6  | 2.1    |

*   *CAGR:*  Shows a potential for growth (9-11% per year) which is not reflecting in its cumulative returns and current stock performance.
*   *MDD:* High Maximum Drawdown values indicate a high level of volatility and risk.
*   *Alpha:* The negative Alpha suggests underperformance relative to its expected return based on its Beta. RXRX is not generating excess return compared to the benchmark.
*   *Beta:*  Beta is above 1, which is consistent with a company with high growth prospects.
*   *Cap:* This suggests a decrease in market capitalization between the two periods, indicating a shrinking company size.

**2) Recent Stock Price Fluctuations:**

*   **Current Close Price:** $4.20
*   **Last Market Data:**
    *   *Price:* $4.20
    *   *Previous Close:* $4.09
    *   *Change:* 2.69% (Indicates a recent increase)
*   **Moving Averages:**
    *   *5-day SMA:* $4.16
    *   *20-day SMA:* $4.43
    *   *60-day SMA:* $4.91

*   **Analysis:** The stock price is currently below both its 20-day and 60-day moving averages, suggesting a short-term downward trend.  The 5-day SMA is closest to the current price, showing a potential slowing of the decline and possible stabilization.

**3) Technical Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 40.10 (Neutral - Not Overbought or Oversold)
*   **PPO:** -0.37 (Negative - Suggests a slight downward trend)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (228 shares - Very Safe - MRI:0.90)"

    *This is conflicting with MRI value in the previous row. It is a very aggressive signal, indicating a strong buy recommendation despite the company's poor performance.*
*   **Recent Relative Divergence Change (20 days):** 2.4 (+) "단기상승" (Short-term Increase)

    *Indicates a recent upward movement in the stock's divergence from its benchmark.*
*   **Large Price Change:** The 2.69% change from the previous close suggests a notable price fluctuation in the last trading session, indicating volatility.
*   **Expected Return (%):** -218.4%

    *Indicates an extremely negative expected return, suggesting high risk and potential for significant losses compared to the S&P 500.*

**4) Recent News & Significant Events:**

*   **Positive News:** Multiple articles highlight positive developments:
    *   JPMorgan Upgrade: A significant upgrade from JPMorgan is a positive catalyst for the stock.
    *   Trial Data Gains: Positive trial data news can boost investor confidence.
    *   "Best Fundamentally Strong Penny Stock": While potentially promotional, it draws attention to the company's fundamentals.
    *   Analyst Upgrade: Further reinforces the potential for positive momentum.
*   **Negative News:** One article points to negative price action:
    *   "RXRX Stock Plummet": This indicates a recent decline in the stock price.
*   **Neutral News:**
    *   Nikko Asset Management Selling Shares: This could create selling pressure on the stock.

*   **Overall Impact:** The news is mixed.  While the JPMorgan upgrade and positive trial data are strong positives, the "stock plummet" article and Nikko's selling activity suggest ongoing challenges.

**4-2) Analyst Opinions:**

*   **Consensus:** No strong consensus indicated.
*   **Target Price:** $7.00 (Average) - A significant upside from the current price, suggesting analysts believe the stock is undervalued.

**5) Recent Earnings Analysis:**

| 날짜         | EPS   | 매출     |
|--------------|-------|----------|
| 2025-11-05 | -0.36 | 0.01 B$  |
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2025-11-05 | -0.34 | 0.03 B$  |

*   **Trend:** Consistent negative EPS values indicate that the company is not currently profitable. Revenue has fluctuated and shown a slight increase, but not enough to offset the losses.

**6) Financial Information:**

Revenue and Profitability:

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.00B   | -194.74%     |
| 2025-06-30 | $0.02B   | -5.54%       |
| 2025-03-31 | $0.01B   | -47.31%      |
| 2024-12-31 | $0.00B   | -183.62%     |
| 2024-09-30 | $0.03B   | 53.69%       |

Capital and Profitability:

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-09-30 | $1.05B   | -15.50%   |
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |

*   **Revenue & Profit Margin:** Highly variable revenue and consistently negative profit margins indicate financial instability and difficulty in generating profits. The large negative profit margins raise concerns about cost management.
*   **Equity & ROE:** Decreasing equity over some periods, combined with negative ROE, further emphasizes the lack of profitability and inefficient use of equity.

**7) Comprehensive Analysis (Summary):**

*   **Negative Performance:** Recursion Pharmaceuticals has significantly underperformed the S&P 500.
*   **Volatility:** High volatility is evident in the maximum drawdown and recent price fluctuations.
*   **Profitability Issues:** The company is currently unprofitable, with negative EPS, negative profit margins, and negative ROE.
*   **Mixed Signals:** While recent news includes positive analyst upgrades and trial data gains, there's also negative news about price drops and share selling. The 'buy' hybrid signal is not supported by other indicators and should be treated with caution.
*   **High Risk:** The extremely negative expected return indicates that investing in RXRX at this point carries a very high level of risk.
*   **Analyst Target:** Positive target prices are not supported by financial information.
*   **Conclusion:** The positive outlook of the most recent indicators does not correspond to the negative company background.

**Recommendation:**

Based on the provided data, investing in Recursion Pharmaceuticals (RXRX) at this time appears **highly risky**. The company's significant underperformance, negative profitability metrics, and high volatility warrant extreme caution. While analyst upgrades and positive trial data offer some hope, they are overshadowed by the company's underlying financial challenges and negative expected return. The Hybrid Signal provides a conflicting outlook with other indicators. A conservative investor would likely avoid this stock until its financial performance improves significantly. Aggressive investors may consider a small, speculative position, acknowledging the substantial risks involved. Further, more in-depth research is necessary before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.